REG - Adv Medical Solutns. - Full Year 2024 Trading Update

Advanced Medical SolutionsAnnouncement

14/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250114:nRSN1524Ta&default-theme=true

RNS Number : 1524T  Advanced Medical Solutions Grp PLC  14 January 2025

14 January 2025

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Full Year 2024 Trading Update
 

~ Enlarged Group performing well and in line with consensus expectations ~

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a world-leading
specialist in tissue-healing technologies, today announces a trading update
for the twelve months ended 31 December 2024. The Group expects to announce
its Full Year results on 19 March 2025.

Following the acquisition of Syntacoll on 1 March 2024 and the transformative
acquisition of Peters Surgical on 1 July 2024, excellent progress has been
made on integrating both businesses, and the enlarged Group is performing
well, with strong growth continuing across all surgical product categories. In
response to changing market dynamics, planned strategic initiatives within the
Woundcare business are also being successfully executed, which are expected to
positively impact margins in 2025.

 

The Group expects to report Full Year 2024 revenues of approximately £177
million (2023: £126.2 million), EBITDA of £40.0 - £40.5 million (2023: £
29.7 million) and adjusted Pre-tax profit of £29.2 - 29.7 million (2023:
£25.9 million).

 

Chris Meredith, Chief Executive Officer of AMS, said: "The progress we made in
the second half of 2024 has strengthened the confidence we have in the
strategic rationale for the recent acquisitions of Peters Surgical and
Syntacoll. The synergistic benefits they represent to AMS, in terms of
products, expertise, geographic reach and scale, are clearer than ever. As we
start the new year as an enlarged and more competitive Group, I remain
confident and excited about the growth and opportunities that we expect in
2025 and beyond."

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc     Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Healthcare                           Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone    AMS@icrhealthcare.com

 Investec Bank PLC (NOMAD & Broker)       Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank plc (Broker)                   Tel: 44 (0) 20 7991 8888
 Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal® brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,500 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

 

-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBJMRTMTJBBBA